An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
CRANFORD, N.J., Aug. 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Las Vegas Virtual Expo that is being held August 18 – 20, 2020.
Event: MoneyShow Las Vegas Virtual Expo
Presentation Date: Wednesday, August 19, 2020
Presentation Time:4:50 PM ET
Mr. Leonard Mazur, Chairman of Citius, will provide an overview of the Company, including the recent closing of a $9.6 million public offering of common stock, and the recent submission of a briefing package to the FDA Division of Anti-Infective Products regarding Mino-Wrap, a novel approach to reducing post-operative infections associated with surgical implants.
To listen to the live webcast, investors will need to register for the MoneyShow Las Vegas Virtual Expo first at the following link:
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.
Contact:
Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 ascott@citiuspharma.com
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.